SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors rally is centered on the pending FDA decision on deramiocel for Duchenne muscular dystrophy: management reiterated confidence on its earnings call and said the application is in final review, while traders interpret its comments about labeling as a possible positive signal. Bulls are anticipating approval and short covering, but others stress that the outcome remains uncertain and a rejection is still possible.

RUM Group, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

Record Q3 revenue growth and Rumbles first positive adjusted EBITDA quarter, driven largely by Quake AIs GPU-computing business, have renewed interest in its shift toward AI infrastructure. Bulls are emphasizing execution and heavy short interest, while skeptics point to continued GAAP losses, financing needs, possible data-center delays and a softer Q4 outlook.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLakes pending FDA decision on whether to accept its sonelokimab application for hidradenitis suppurativa is the main focus, with traders also citing competitor trial results as support for the drugs prospects. Bulls see room for a recovery, while skeptics stress that acceptance is not approval and question competition, launch costs, and the companys plan to commercialize on its own.

Figure Technology Solutions, Inc. is a blockchain-native capital marketplace, which engages in connecting origination, funding, and secondary market activity. It operates through the following segments: FTI, Markets, and Other. The FTI segment offers Figure Connect which generates ecosystem and technology fees, and originates, sells, and securitizes home equity line of credit (HELOC) loans that it services. The Markets segment utilizes blockchain technology to develop an exchange for digital assets and credit, with new product offerings including providing interest-bearing stable coin deposits. The company was founded by Michael Scott Cagney and June Ou in 2018 and is headquartered in Reno, NV.

Figure Technology Solutions Inc. - Ordinary Shares - Class A

Figure Technology Solutions Inc

Traders are attributing FIGRs sharp move to revised 2028 earnings expectations, though that explanation is not broadly corroborated in the discussion. The community remains split between optimism about growth and HELOC demand and concerns about crypto weakness, valuation, and short-selling pressure.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves stronger-than-expected quarterly results and raised outlook, alongside its large backlog and customer prepayments, eased some concerns about funding its AI infrastructure expansion; the CEOs canceled stock-sale plan also drew bullish notice. Traders celebrated the sharp rebound and speculated about a short squeeze, while skeptics continued to flag debt, interest costs, heavy spending, and potential dilution.

Amprius Technologies, Inc. engages in the development, manufacture, and market of lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the following geographical segments: North America, EMEA, and Asia Pacific. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius quarterly results are driving attention: revenue growth, improved margins and raised guidance drew praise, while an EPS miss and negative adjusted EBITDA weighed on the shares. Traders are debating the selloff despite the stronger outlook, with some attributing it to short-term trading pressure, though that explanation is speculative.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

AbCelleras positive Phase 2 results for ABCL635, its investigational treatment for menopausal hot flashes, and CEO comments on its commercial potential are driving attention, alongside Q3 results, pipeline additions and analyst upgrades. The community is largely bullish, but some traders are frustrated by the weak price reaction and emphasize that durability and later-stage trial execution remain unproven.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It operates through the following segments: Uranium, Rare Earth Elements (REE), and Heavy Mineral Sands (HMS). The uranium segment engages in conventional and ISR uranium extraction, recovery and sales of uranium from mineral properties and the recycling of uranium-bearing materials generated by third parties along with the exploration, permitting and evaluation of uranium properties in the U.S. The REE segment is engaged in the company’s initiatives to progress towards full REE separation capabilities at the Mill to produce both light and heavy separated REE oxides in the coming years. The HMS segment engages in the exploration, development and recovery of HMS at the Kwale Project, Bahia Project, Vara Mada Project and the company’s equity method investments in the Donald Project JV and Tate. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels sharp, sustained selloff and underperformance versus uranium and rare-earth peers dominate discussion, with traders pointing to dilution and financing concerns and uncertainty around the planned VAC acquisition after GM canceled a key supply agreement. Some see the drop as evidence the strategy is too risky, while bullish holders say the longer-term uranium and rare-earth supply-chain thesis remains intact.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines quarterly update highlighted a strong early launch for RASONQUE, its newly approved pancreatic cancer drug, but the shares sold off despite the upbeat sales reception. Traders are debating whether the decline reflects profit-taking and concerns about sustaining the launch amid high spending, or an overreaction to results that otherwise showed promising initial demand.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

Golds sharp pullback is drawing attention as hotter-than-expected inflation strengthened the dollar and Treasury yields and revived expectations of Fed rate hikes, pressures for a non-yielding asset. Traders are split between bearish calls for further losses and dip-buying or bounce hopes around technical support.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


Share

Sam